CoVPN Cross-Protocol Analyses
- Funded by National Institutes of Health (NIH)
- Total publications:0 publications
Grant number: 3UM1AI068635-15S3
Grant search
Key facts
Disease
COVID-19Start & end year
20212022Known Financial Commitments (USD)
$589,642Funder
National Institutes of Health (NIH)Principal Investigator
Peter GilbertResearch Location
United States of AmericaLead Research Institution
FRED HUTCHINSON CANCER RESEARCH CENTERResearch Priority Alignment
N/A
Research Category
Vaccines research, development and implementationResearch Subcategory
N/ASpecial Interest Tags
Data Management and Data SharingStudy Type
Not applicableClinical Trial Details
N/ABroad Policy Alignment
PendingAge Group
Not ApplicableVulnerable Population
Not applicableOccupations of Interest
Not applicable
Abstract
Project Abstract This proposal outlines the scientific agenda for the COVID-19 Prevention Network (CoVPN) Vaccines Statistical and Data Management Center (SDMC) for implementation of cross-protocol work in support of COVID-19 phase 3 efficacy trials. With the global COVID-19 pandemic, we recognize a significant need for vaccines that modify COVID-19 in SARS-CoV-2 infected individuals. Addressing this gap, the HVTN SDMC has joined 4 other National Institute of Health (NIH) clinical trial networks to form the CoVPN, an enhanced network dedicated to developing globally effective vaccines for SARS-CoV-2. The innovation of the CoVPN SDMC and advantages to this work include the collective experience of our group- leader in statistical methods in vaccine evaluation, especially immune correlates assessment, and the long-standing relationships we have with the clinical and lab groups in the CoVPN lead Adapting and leveraging statistical methods for evaluating vaccines against other pathogens to SARS-CoV-2. E.g. causal inference methods for evaluating multiple types of formally defined correlates of protection including correlates of vaccine efficacy, mediators of vaccine efficacy, and stochastic-intervention effects on vaccine efficacy.